Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384564697> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W4384564697 endingPage "115594" @default.
- W4384564697 startingPage "115594" @default.
- W4384564697 abstract "This article describes the development and validation of a liquid-chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay for the simultaneous quantitation of the BRAF inhibitors dabrafenib and encorafenib, and semi-quantitation of their major metabolites (i.e., carboxy-dabrafenib, desmethyl-dabrafenib, hydroxy-dabrafenib, M42.5A) in human plasma. Analytes were extracted from human plasma by protein precipitation, followed by reversed phase high-performance liquid chromatography. Analyte detection was performed using tandem mass spectrometry with heated electrospray ionization operating in positive ion mode. The assay was validated in accordance with the current U.S. Food and Drug Administration Guidance on Bioanalytical Method Validation. Results showed that measurements were both accurate (94.6-112.0 %) and precise (within-run: 1.9-3.4 %; between-run: 1.7-12.0 %) spanning a concentration range of 5 to 2000 ng/mL for dabrafenib and 10 to 4000 ng/mL for encorafenib. Recoveries for these analytes were consistent with mean values ranging from 85.6 % to 90.9 %. The mean internal standard-normalized matrix factors for each drug ranged between 0.87 and 0.98 and were found to be precise (% RSD <6.4 %). Dabrafenib and encorafenib were stable in the final extract and in human plasma held under various storage conditions. The metabolites also passed the validation criteria for precision and selectivity. Finally, the clinical applicability of the assay was confirmed by (semi-)quantitation of all six analytes in plasma samples from cancer patients receiving standard-of-care treatment with dabrafenib and encorafenib. Reproducibility of the measured analyte concentrations in study samples was confirmed successfully by incurred sample reanalysis. In conclusion, this sensitive LC-MS/MS assay has been validated successfully and is suitable for therapeutic drug monitoring of dabrafenib and encorafenib and clinical pharmacokinetic studies with these BRAF inhibitors." @default.
- W4384564697 created "2023-07-18" @default.
- W4384564697 creator A5049243227 @default.
- W4384564697 creator A5051618785 @default.
- W4384564697 creator A5092487124 @default.
- W4384564697 date "2023-09-01" @default.
- W4384564697 modified "2023-10-17" @default.
- W4384564697 title "Development and validation of an LC–MS/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma" @default.
- W4384564697 cites W1549428774 @default.
- W4384564697 cites W2050359740 @default.
- W4384564697 cites W2071699268 @default.
- W4384564697 cites W2135925159 @default.
- W4384564697 cites W2160766792 @default.
- W4384564697 cites W2163795546 @default.
- W4384564697 cites W2491982852 @default.
- W4384564697 cites W2519707533 @default.
- W4384564697 cites W2553089427 @default.
- W4384564697 cites W2607104335 @default.
- W4384564697 cites W2607437944 @default.
- W4384564697 cites W2770262472 @default.
- W4384564697 cites W2770461290 @default.
- W4384564697 cites W2791879821 @default.
- W4384564697 cites W2793817570 @default.
- W4384564697 cites W2909908811 @default.
- W4384564697 cites W2990074943 @default.
- W4384564697 cites W3095485440 @default.
- W4384564697 cites W3096013830 @default.
- W4384564697 cites W3101630206 @default.
- W4384564697 cites W3134231065 @default.
- W4384564697 cites W3159632549 @default.
- W4384564697 cites W3164187146 @default.
- W4384564697 cites W4283710798 @default.
- W4384564697 cites W4294724539 @default.
- W4384564697 doi "https://doi.org/10.1016/j.jpba.2023.115594" @default.
- W4384564697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37478552" @default.
- W4384564697 hasPublicationYear "2023" @default.
- W4384564697 type Work @default.
- W4384564697 citedByCount "0" @default.
- W4384564697 crossrefType "journal-article" @default.
- W4384564697 hasAuthorship W4384564697A5049243227 @default.
- W4384564697 hasAuthorship W4384564697A5051618785 @default.
- W4384564697 hasAuthorship W4384564697A5092487124 @default.
- W4384564697 hasConcept C10390740 @default.
- W4384564697 hasConcept C121608353 @default.
- W4384564697 hasConcept C126322002 @default.
- W4384564697 hasConcept C137535248 @default.
- W4384564697 hasConcept C162356407 @default.
- W4384564697 hasConcept C185592680 @default.
- W4384564697 hasConcept C194451485 @default.
- W4384564697 hasConcept C2776131300 @default.
- W4384564697 hasConcept C2778830669 @default.
- W4384564697 hasConcept C2994587330 @default.
- W4384564697 hasConcept C31827203 @default.
- W4384564697 hasConcept C40684141 @default.
- W4384564697 hasConcept C43617362 @default.
- W4384564697 hasConcept C64489805 @default.
- W4384564697 hasConcept C71924100 @default.
- W4384564697 hasConcept C74774607 @default.
- W4384564697 hasConceptScore W4384564697C10390740 @default.
- W4384564697 hasConceptScore W4384564697C121608353 @default.
- W4384564697 hasConceptScore W4384564697C126322002 @default.
- W4384564697 hasConceptScore W4384564697C137535248 @default.
- W4384564697 hasConceptScore W4384564697C162356407 @default.
- W4384564697 hasConceptScore W4384564697C185592680 @default.
- W4384564697 hasConceptScore W4384564697C194451485 @default.
- W4384564697 hasConceptScore W4384564697C2776131300 @default.
- W4384564697 hasConceptScore W4384564697C2778830669 @default.
- W4384564697 hasConceptScore W4384564697C2994587330 @default.
- W4384564697 hasConceptScore W4384564697C31827203 @default.
- W4384564697 hasConceptScore W4384564697C40684141 @default.
- W4384564697 hasConceptScore W4384564697C43617362 @default.
- W4384564697 hasConceptScore W4384564697C64489805 @default.
- W4384564697 hasConceptScore W4384564697C71924100 @default.
- W4384564697 hasConceptScore W4384564697C74774607 @default.
- W4384564697 hasLocation W43845646971 @default.
- W4384564697 hasLocation W43845646972 @default.
- W4384564697 hasOpenAccess W4384564697 @default.
- W4384564697 hasPrimaryLocation W43845646971 @default.
- W4384564697 hasRelatedWork W1989080374 @default.
- W4384564697 hasRelatedWork W1997260764 @default.
- W4384564697 hasRelatedWork W2058346847 @default.
- W4384564697 hasRelatedWork W2066528856 @default.
- W4384564697 hasRelatedWork W2077683086 @default.
- W4384564697 hasRelatedWork W2205101293 @default.
- W4384564697 hasRelatedWork W2936345590 @default.
- W4384564697 hasRelatedWork W3023432142 @default.
- W4384564697 hasRelatedWork W3028635380 @default.
- W4384564697 hasRelatedWork W4312445045 @default.
- W4384564697 hasVolume "234" @default.
- W4384564697 isParatext "false" @default.
- W4384564697 isRetracted "false" @default.
- W4384564697 workType "article" @default.